We’ve all had a moment where we arrived at the grocery store and can’t remember passing any of the stoplights along the way. We’re halfway down an aisle and scrambling to remember what we even needed. Our mind is in overdrive trying to sort through our ever-growing to-do list. We’ve been there when just making it through the next task is hard. But the normal stresses of life aren’t the only thing YOU have to deal with. Nora McInerny hosts The Head Start: Embracing the Journey, a new podcast ...
…
continue reading
Вміст надано The Alpha Human Podcast. Весь вміст подкастів, включаючи епізоди, графіку та описи подкастів, завантажується та надається безпосередньо компанією The Alpha Human Podcast або його партнером по платформі подкастів. Якщо ви вважаєте, що хтось використовує ваш захищений авторським правом твір без вашого дозволу, ви можете виконати процедуру, описану тут https://uk.player.fm/legal.
Player FM - додаток Podcast
Переходьте в офлайн за допомогою програми Player FM !
Переходьте в офлайн за допомогою програми Player FM !
Doctor Says No Treatment For This Cancer: Here's What They Missed!
MP3•Головна епізоду
Manage episode 357352994 series 3072470
Вміст надано The Alpha Human Podcast. Весь вміст подкастів, включаючи епізоди, графіку та описи подкастів, завантажується та надається безпосередньо компанією The Alpha Human Podcast або його партнером по платформі подкастів. Якщо ви вважаєте, що хтось використовує ваш захищений авторським правом твір без вашого дозволу, ви можете виконати процедуру, описану тут https://uk.player.fm/legal.
In the latest episode of the Alpha Human Podcast, Lawrence shares his experience of delving into the medical literature for six months after being told that other than surgery, there were no effective treatments for his type of cancer. The results of his genetic analysis showed that his tumor had a mutation of the DDX41 gene, responsible for creating a protein that suppresses certain oncogenes, such as KIT. What's more, he discovered that his tumor not only expressed higher levels of the kinase receptor protein C-KIT compared to normal cells, but he also learned has a KIT mutation. This is noteworthy because KIT activating mutations are typically never seen in chromophobe renal cell carcinoma (ChRCC), which is Lawrence's cancer type. This finding could have significant implications for targeted therapies, such as Tyrosine Kinase Inhibitors, which although usually ineffective in chRCC, may work in Lawrence's case due to his unique mutation profile. The episode also highlights a scientific paper from 2019 that reported on a patient with metastatic ChRCC who had an exceptional response to Sunitinib, despite tyrosine kinase inhibitors (TKIs) not being typically effective for this type of cancer. The patient had increased expression of VEGF-C and VEGF-B, which could be utilized as biomarkers to guide ChRCC patients toward TKI therapy. Lawrence stresses the importance of doing your own research and taking control of your health, especially when dealing with serious medical conditions. The content of this podcast and any information, advice, opinions, or statements within it are not intended and are not to be used as a substitute for professional medical advice, diagnosis, or treatment. You should not disregard or delay in obtaining medical advice for any medical condition you may have, and you should seek the assistance of a healthcare professional for any such conditions, and always inform your doctor of any changes you make to your lifestyle. DDX41 regulates the expression and alternative splicing of genes involved in tumorigenesis and immune response": https://www.spandidos-publications.com/10.3892/or.2021.7951 Overexpression of KIT in chromophobe renal cell carcinoma: https://www.nature.com/articles/1206153 C-kit overexpression is not associated with KIT gene mutations in chromophobe renal cell carcinoma or renal oncocytoma https://www.sciencedirect.com/science/article/abs/pii/S034403381400123X Tyrosine Kinase Inhibitors and Angiogenesis: https://www.sciencedirect.com/science/article/pii/B9780128025765000085 Determinants of resistance to VEGF-TKI and immune checkpoint inhibitors in metastatic renal cell carcinoma https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8183071/ Exceptional Response of Metastatic Chromophobe Renal Cell Carcinoma to Vascular Endothelial Growth Factor (VEGF) Inhibitors: Should Increased VEGF-C Expression Be Used to Guide Treatment? https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6949673/ Vascular Endothelial Growth Factor (VEGF) and Its Receptor (VEGFR) Signaling in Angiogenesis https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3411125/ Expression of vascular endothelial growth factor C in renal cell carcinoma and its correlation with pathological parameters and prognosis https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7475675/ The content of this podcast, and any information, advice, opinions, or statements within it are not intended and are not to be used as a substitute for professional medical advice, diagnosis, or treatment. You should not disregard or delay in obtaining medical advice for any medical condition you may have, and you should seek the assistance of a healthcare professional for any such conditions, and always inform your doctor of any changes you make to your lifestyle. #cancer #kidneycancer #rcc #chromophobecancer
…
continue reading
64 епізодів
MP3•Головна епізоду
Manage episode 357352994 series 3072470
Вміст надано The Alpha Human Podcast. Весь вміст подкастів, включаючи епізоди, графіку та описи подкастів, завантажується та надається безпосередньо компанією The Alpha Human Podcast або його партнером по платформі подкастів. Якщо ви вважаєте, що хтось використовує ваш захищений авторським правом твір без вашого дозволу, ви можете виконати процедуру, описану тут https://uk.player.fm/legal.
In the latest episode of the Alpha Human Podcast, Lawrence shares his experience of delving into the medical literature for six months after being told that other than surgery, there were no effective treatments for his type of cancer. The results of his genetic analysis showed that his tumor had a mutation of the DDX41 gene, responsible for creating a protein that suppresses certain oncogenes, such as KIT. What's more, he discovered that his tumor not only expressed higher levels of the kinase receptor protein C-KIT compared to normal cells, but he also learned has a KIT mutation. This is noteworthy because KIT activating mutations are typically never seen in chromophobe renal cell carcinoma (ChRCC), which is Lawrence's cancer type. This finding could have significant implications for targeted therapies, such as Tyrosine Kinase Inhibitors, which although usually ineffective in chRCC, may work in Lawrence's case due to his unique mutation profile. The episode also highlights a scientific paper from 2019 that reported on a patient with metastatic ChRCC who had an exceptional response to Sunitinib, despite tyrosine kinase inhibitors (TKIs) not being typically effective for this type of cancer. The patient had increased expression of VEGF-C and VEGF-B, which could be utilized as biomarkers to guide ChRCC patients toward TKI therapy. Lawrence stresses the importance of doing your own research and taking control of your health, especially when dealing with serious medical conditions. The content of this podcast and any information, advice, opinions, or statements within it are not intended and are not to be used as a substitute for professional medical advice, diagnosis, or treatment. You should not disregard or delay in obtaining medical advice for any medical condition you may have, and you should seek the assistance of a healthcare professional for any such conditions, and always inform your doctor of any changes you make to your lifestyle. DDX41 regulates the expression and alternative splicing of genes involved in tumorigenesis and immune response": https://www.spandidos-publications.com/10.3892/or.2021.7951 Overexpression of KIT in chromophobe renal cell carcinoma: https://www.nature.com/articles/1206153 C-kit overexpression is not associated with KIT gene mutations in chromophobe renal cell carcinoma or renal oncocytoma https://www.sciencedirect.com/science/article/abs/pii/S034403381400123X Tyrosine Kinase Inhibitors and Angiogenesis: https://www.sciencedirect.com/science/article/pii/B9780128025765000085 Determinants of resistance to VEGF-TKI and immune checkpoint inhibitors in metastatic renal cell carcinoma https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8183071/ Exceptional Response of Metastatic Chromophobe Renal Cell Carcinoma to Vascular Endothelial Growth Factor (VEGF) Inhibitors: Should Increased VEGF-C Expression Be Used to Guide Treatment? https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6949673/ Vascular Endothelial Growth Factor (VEGF) and Its Receptor (VEGFR) Signaling in Angiogenesis https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3411125/ Expression of vascular endothelial growth factor C in renal cell carcinoma and its correlation with pathological parameters and prognosis https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7475675/ The content of this podcast, and any information, advice, opinions, or statements within it are not intended and are not to be used as a substitute for professional medical advice, diagnosis, or treatment. You should not disregard or delay in obtaining medical advice for any medical condition you may have, and you should seek the assistance of a healthcare professional for any such conditions, and always inform your doctor of any changes you make to your lifestyle. #cancer #kidneycancer #rcc #chromophobecancer
…
continue reading
64 епізодів
Tous les épisodes
×Ласкаво просимо до Player FM!
Player FM сканує Інтернет для отримання високоякісних подкастів, щоб ви могли насолоджуватися ними зараз. Це найкращий додаток для подкастів, який працює на Android, iPhone і веб-сторінці. Реєстрація для синхронізації підписок між пристроями.